triiodothyronine has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 3 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum prolactin (PRL), thyroid-stimulating hormone (TSH), thyroxine (free T4), free tri-iodothyronine (free T3), insulin resistance (IR) which was estimated by the homeostasis model assessment, thyroidal microsome (anti-TPO), antithyroglobulin antibodies (TgAb), estradiol (E2), and insulin like growth factor (IGF-1) were evaluated, and thyroid volume was calculated by B-mode doppler USG." | 3.81 | Are there any causes for increased thyroid volume in women with prolactinoma? ( Arduç, A; Berker, D; Doğan, BA; Güler, S; Müslüm Tuna, M; Taşcı, T, 2015) |
| "In 21 patients with prolactinomas resistant to bromocriptine, we studied the effects of CV 205-502 on PRL hypersecretion and tumor mass, as assessed by consecutive computed tomography examinations." | 1.28 | Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. ( Brownell, J; Brue, T; Dewailly, D; Enjalbert, A; Gunz, G; Jaquet, P; Morange, I; Pellegrini, I, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doğan, BA | 1 |
| Taşcı, T | 1 |
| Arduç, A | 1 |
| Müslüm Tuna, M | 1 |
| Berker, D | 1 |
| Güler, S | 1 |
| Brue, T | 1 |
| Pellegrini, I | 1 |
| Gunz, G | 1 |
| Morange, I | 1 |
| Dewailly, D | 1 |
| Brownell, J | 1 |
| Enjalbert, A | 1 |
| Jaquet, P | 1 |
| Eskildsen, PC | 1 |
| Kruse, A | 1 |
| Kirkegaard, C | 1 |
3 other studies available for triiodothyronine and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Are there any causes for increased thyroid volume in women with prolactinoma?
Topics: Adult; Autoantibodies; Estradiol; Female; Humans; Insulin Resistance; Insulin-Like Growth Factor I; | 2015 |
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Topics: Adult; Aminoquinolines; Antineoplastic Agents; Bromocriptine; Dopamine Agents; Dose-Response Relatio | 1992 |
The pituitary-thyroid axis in patients with pituitary disorders.
Topics: Adenoma; Adult; Aged; Craniopharyngioma; Euthyroid Sick Syndromes; Female; Follow-Up Studies; Humans | 1989 |